Navigation Links
OncoSec Medical to Present at Noble Financial Capital Markets' Ninth Annual Equity Conference on January 22
Date:1/17/2013

SAN DIEGO, Jan. 17, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon , President and CEO, will present at the Noble Financial Capital Markets' Ninth Annual Equity Conference, at the Hard Rock Hotel in Hollywood, Florida, on Tuesday, January 22 at 12:30 PM Eastern Time.

(Logo:  http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)

At the time of the presentation, a live audio and high-definition video webcast of OncoSec's presentation will be available through the Noble Financial website: www.noblefcm.com. It is recommended that those who are interested should register at least 10 minutes prior to the start of the presentation to ensure timely access. A Microsoft Silverlight viewer, available for free download from the presentation link, will be required to participate.

In addition, OncoSec will be a sponsor of the European School of Dermato-Oncology (EADO) meeting in Berlin, Germany from January 17-19. Company delegates will be attending and participating in the meeting.

About Noble Financial Capital Markets

Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service, investment banking boutique focused on life sciences, technology and media, emerging growth, companies. The company has offices in New York, Boston, New Jersey, Los Angeles, and Boca Raton, FL. For more information: www.noblefcm.com

About the European School of D
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: ... leading retail drugstore chain in China ... today announced the appointment of Ms. Rebecca Yingnan ... immediately. Ms.Zhang has over 20 years ... in March 1999. Prior to Ms. Zhang,s appointment as ...
(Date:11/24/2014)... Juno Therapeutics today announced that the ... company,s JCAR015 chimeric antigen receptor product candidate.  The ... refractory B-cell acute lymphoblastic leukemia and was filed ... Center, where Phase 1 clinical trials are currently ... important news for patients who may benefit from ...
(Date:11/24/2014)... YORK , Nov. 24, 2014  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to present at the LD MICRO "MAIN Event" Micro-Cap ... will be held at the Luxe Sunset Bel Air ... Los Angeles, California . ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2
... NEW YORK, Dec. 6, 2010 Keryx Biopharmaceuticals, ... data presented for the first time at the ... Hematology showing promising clinical activity, safety and tolerability ... leukemia (CLL) and Hodgkin,s lymphoma (HL).  KRX-0401 (perifosine) ...
... L.P. unveiled an enhanced version of its popular educational ... easier for healthcare professionals, people with pain and their ... tools. For more than 17 years, the Partners Against ... the quality of pain management for individuals touched by ...
Cached Medicine Technology:Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 2Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 3Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 4Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 5Purdue Pharma L.P. Re-launches Partners Against Pain Website 2
(Date:11/26/2014)... (PRWEB) November 26, 2014 Louisiana ... relief and specialists in minimally invasive spine surgery, ... Shamieh into the rapidly growing provider network of ... The addition coincides with the network’s continuing success ... treatment for Louisiana residents who are suffering from ...
(Date:11/26/2014)... 2014 Sonoran Vein and Endovascular ... the Distinguished Preceptorship Award from The American ... in the advancement of nurse practitioners. The Distinguished ... who had made a significant contribution toward increasing ... Association of Nurse Practitioners (AANP) is the largest ...
(Date:11/26/2014)... Nov. 25, 2014 (HealthDay News) -- Youngsters who enter ... new study suggests. Early puberty was linked with ... poor self-image and high anxiety levels, according to the ... such as conflict with family and peers, and having ... study found. Although the study found an association ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Teens prescribed anti-anxiety ... abuse those drugs than other teens, a new ... to conduct substance abuse assessments on teenagers before ... "Prescribers and parents don,t realize the abuse ... at the University of Michigan School of Nursing. ...
(Date:11/26/2014)... Exposure to peanut protein in household dust may increase ... skin condition eczema, a new study reveals. About ... are allergic to peanuts. And severe eczema in infants ... the researchers noted. The new study included 359 ... examined the amount of peanut protein the children were ...
Breaking Medicine News(10 mins):Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2
... weight loss drugs are really safe, an analysis of previous ... was conducted. What// came to light was the lack of ... ,Two Canadian researchers, Raj Padwal and Sumit Majumdar of ... like sibutramine (Meridia), orlistat (Xenical) and rimonabant (Acomplia) are no ...
... new proposal released by Gov. Arnold Schwarzenegger recently, workers ... double benefit - to their// health and wealth. Employees ... be exempted from tax. ,The proposal is ... is reachable to the approximate 6.5 million Californians who ...
... towards understanding how the human brain learns to recognize ... of Technology, in 2003 launched a project to study ... Prakash" aims to study, identify and, treat, children who ... a lady born blind was studied by the professor, ...
... India plans to promote the development of public-private partnerships ... the National AIDS Control Programme (NACP-III) is likely to ... that approx. 80 per cent of the Indians seek ... per cent for inpatient care. ,A national ...
... diabetes mellitus (NODM) develops in certain patients following a liver ... to develop//, finds that all the risk factors can be ... tailored to the patient's risk ,They found the ... and hepatitis C infection (HCV) paired with the use of ...
... Prevention (CDC) Atlanta's Division of Tuberculosis Elimination feel that ... made TB tests mandatory for all foreign-born nationals, irrespective ... ,Tuberculosis can only be eradicated if all foreign-born ... treated for latent TB infection, they say. ...
Cached Medicine News:Health News:Latest Research on Visual Skills is an Eye Opener 2Health News:Risk Factors That Cause NODM After A Liver Transplant 2Health News:All Foreign-born Nationals In US To Be Tested For TB 2
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large devices for vascular intervention....
Used to introduce balloon, closed and non-tapered end catheters and other devices for intervention....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Medicine Products: